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Summary
The role of symbiotic bacteria in the development of antigen-specific
immunity remains poorly understood. Previous studies showed that sens-
ing of symbiotic bacteria by nucleotide-binding oligomerization domain-
containing protein 2 (Nod2) regulates antibody responses in response to
nasal immunization with antigen and cholera toxin (CT). In this study,
we examined the role of the microbiota in the adjuvant activity of CT
induced after oral immunization with antigen. Germ-free (GF) mice
showed impaired production of antibody responses and T-cell-specific
cytokines after oral immunization when compared with that observed in
conventionally raised mice. Similar to GF mice, Nod2-deficient mice
showed reduced humoral responses upon oral immunization with antigen
and CT. Treatment with CT enhanced the production of interleukin-1b
(IL-1b), but not tumor necrosis factor-a or IL-12p40, induced by stimula-
tion of dendritic cells with muramyl dipeptide, the Nod2 ligand. Mecha-
nistically, the enhanced production of IL-1b induced by muramyl
dipeptide and CT stimulation required Nod2 and was mediated by both
increased synthesis of pro-IL-1b and caspase-1 activation. Furthermore,
antigen-specific antibody and cytokine responses induced by CT were
impaired in orally immunized IL-1b-deficient mice. Collectively, our
results indicate that Nod2 stimulation by symbiotic bacteria contributes
to optimal CT-mediated antigen-specific oral vaccination through the
induction of IL-1b production.
Keywords: adjuvant; cholera toxin; interleukin-1b; microbiota; Nod2;
symbiotic bacteria.
Introduction
Cholera toxin (CT), an enterotoxin secreted by the bac-
terium Vibrio cholerae, is responsible for the massive diar-
rhea that is characteristic of cholera infection.1 The CT
protein complex is composed of one A subunit and five
B subunits. The A subunit exhibits adenosine diphos-
phate-ribosyltransferase activity, which activates the gua-
nine nucleotide-binding protein Gsa and, in turn,
adenylate cyclase, thereby increasing intracellular levels of
cyclic adenosine monophosphate (cAMP). In contrast, the
B subunit plays a role in the binding of the toxin to GM1
ganglioside receptors found on the host cell surfaces.1–4
CT is known to exhibit a potent adjuvant activity, mainly
linked to the activity of its monomeric A subunit.5 How-
ever, CT holotoxin is too toxic for human use.1 Despite
extensive studies on the mechanism underlying the adju-
vant activity of CT, the lack of sufficient understanding
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has hampered the development of non-toxic but effective
adjuvants based on this toxin.
Cholera toxin is known to promote mucosal and sys-
temic immune responses. Treatment with CT drives naive
T cells toward T helper type 2 (Th2) type responses.6,7
However, other reports have shown that the toxin also
promotes Th1 and Th17 differentiation through a cAMP-
dependent pathway, which might be required for its adju-
vant activity.8,9 CT activates T cells by inducing the pro-
duction of cytokines from antigen-presenting cells and
co-stimulatory molecules on the cell surface.10 In addi-
tion, the toxin enhances the antigen presentation capacity
of antigen-presenting cells, an initial step in the adaptive
immune response, through a cAMP-dependent path-
way.11,12 Collectively these studies show that the effect of
CT on antigen-presenting cells might be critical to its
ability to promote adaptive immunity.
The microbiota plays an important role in the induc-
tion of immune cell populations, development of gut-as-
sociated lymphoid tissues, and protection against viral
and bacterial infections.13,14 Moreover, the microbiota
enhances immune responses induced by unadjuvanted
and inactivated influenza vaccines through stimulation of
the Toll-like receptor 5 (TLR5) receptor.15 In addition,
symbiotic bacteria located in the nasal cavity enhance
antibody responses induced by nasal immunization with
antigen and CT.16 Although the gastrointestinal tract is
where most symbiotic bacteria reside, the contribution of
the gut microbiota to oral vaccination remains unclear.
Members of the nucleotide-binding oligomerization
domain (Nod)-like receptor (NLR) family function as
intracellular pattern recognition receptors to activate host
immunity in response to microbial products and damage-
associated signals.17 The NLR family member Nod2 recog-
nizes the muramyl dipeptide (MDP) motif, which is con-
served in peptidoglycan produced by both Gram-negative
and Gram-positive bacteria.18–20 Upon stimulation, Nod2
activates nuclear factor-jB and mitogen-activated protein
kinases to induce expression of pro-inflammatory and
antimicrobial molecules.18–21 MDP exhibits adjuvant
activity and induces predominant Th2 responses and, in
combination with TLR agonists, promotes the production
of a high level of antigen-specific antibody in mice.22,23 In
addition, Nod2-mediated recognition of the microbiota
plays a critical role in the mucosal adjuvant activity of CT
induced via the nasal route.16 Here, we examined the role
of the microbiota and Nod2 in antibody responses
induced by oral immunization with antigen and CT.
Material and methods
Mice
Wild-type (WT), Nod2/, and Ilb1/ mice on a C57BL/6
background were bred and maintained under specific
pathogen-free (SPF) conditions at the University of Michi-
gan Animal Facility. C57BL/6 mice purchased from Orient
Bio Inc. (Seongnam, Korea) were held under SPF condi-
tions in an animal facility at Wide River Institute of
Immunology of Seoul National University College of Medi-
cine. Nod2/ mice were bred and held under SPF condi-
tions in an animal facility at Wide River Institute of
Immunology of Seoul National University College of Medi-
cine. Germ-free (GF) C57BL/6 mice were bred and main-
tained at the GF Animal Core Facility of the University of
Michigan. Mice were allocated randomly into experimental
groups. We performed all experimental procedures in
accordance with protocols approved by the University
Committee on Use and Care of Animals at the University
of Michigan and by the Institutional Animal Care and Use
Committee at the Seoul National University Hospital.
Reagents
Cholera toxin (List Biological Laboratories, Campbell,
CA), human serum albumin (HSA; Talecris Biotherapeu-
tics, Research Triangle Park, NC, or Sigma-Aldrich, St
Louis, MO), MDP (Bachem, Saint Helen’s, UK), Ultra-
pure lipopolysaccharide (LPS) (InvivoGen, San Diego,
CA), Pam3 (Pam3CSK4; InvivoGen), lipoteichoic acid
(InvivoGen), PolyI:C (PolyI:C HMW; InvivoGen), CpG
(ODN 1826; InvivoGen), CT A subunit (List Biological
Laboratories), 8-Br-cAMP (Sigma-Aldrich), N6-benzoyl-
cAMP (BioLog Life Science Institute, Bremen, Germany),
8-CPT-20-O-Me-cAMP (Enzo Life Sciences, Farmingdale,
NY), and H-89 (InvivoGen) were purchased from the
indicated commercial sources. Interleukin-1b (IL-1b) anti-
body was purchased from R&D Systems (Minneapolis,
MN) and antibodies for glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) and b-actin were obtained from
Santa Cruz Biotechnology (Dallas, TX); antibody against
caspase-1 was generated in our laboratory.
Immunization protocol
We orogastrically immunized 7- to 10-week-old age- and
sex-matched mice with 200 ll of distilled water contain-
ing 10 mg of HSA and 10 lg of CT by gavage. Mice were
killed and then blood and spleen were obtained for analy-
sis at 2 weeks after immunization or at the indicated
time-points. For the GF experiments, all reagents were
autoclaved or passed through 02-lm filters (Corning,
Corning, NY) before immunization. No animals or sam-
ples used in the mouse experiments were excluded from
the analyses.
Measurement of HSA-specific antibodies
Mouse blood samples were collected in plasma separator
tubes with lithium heparin (BD Biosciences, Franklin
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Lakes, NJ), and plasma was separated by centrifugation.
Mouse feces were suspended in phosphate-buffered saline
(100 mg/ml) by vigorous vortexing. ELISA plates were
coated with HSA and levels of HSA-specific total IgG,
IgA, IgG1, IgG2b and IgM were measured using an indi-
rect ELISA method based on the manufacturer’s instruc-
tions (SBA ClonotypingTM System/AP; SouthernBiotech,
Birmingham, AL).
Re-stimulation of splenocytes
Splenocytes were isolated from spleens on day 14 after
immunization as previously described.24 Briefly, spleens
were mashed through a cell strainer (Falcon, Thermo
Fisher Scientific, Waltham, MA), and then the cells were
spun down and resuspended in red blood cell lysis buffer
(eBioscience, San Diego, CA). After 5 min, the cells were
rinsed with complete RPMI-1640 medium containing
10% heat-inactivated fetal bovine serum, 2-b-mercap-
toethanol (50 lM), L-glutamine (2 mM), sodium pyruvate
(1 mM), minimum essential medium non-essential amino
acids, and penicillin–streptomycin (Gibco, Waltham, MA)
and pushed through the cell strainer. Isolated splenocytes
(2 9 106 cells in 200 ll inoculated into each well in a
48-well plate) were resuspended in complete RPMI-1640
medium and re-stimulated with 500 lg/ml of HSA. After
4 days, culture supernatants were harvested and analyzed
for cytokines by ELISA.
Bone-marrow-derived dendritic cell culture conditions
and in vitro stimulation
Bone-marrow-derived dendritic cells (DCs) were gener-
ated by differentiating bone marrow progenitors isolated
from femurs and tibiae of a mouse in RPMI-1640
medium containing 10% heat-inactivated fetal bovine
serum, 2-mercaptoethanol (50 lM), penicillin–strepto-
mycin and 20 ng/ml of granulocyte–macrophage col-
ony-stimulating factor (GM-CSF; PeproTech, Rocky
Hill, NJ) and were supplemented with fresh medium
on days 3 and 5. On day 7 after bone marrow isola-
tion, non-adherent cells were collected as differentiated
DCs by vigorous aspiration. Dendritic cells (4 9 105
cells in 200 ll inoculated into each well in a 48-well
plate) were stimulated with MDP (10 lg/ml) or LPS
(100 ng/ml) and, 30 min later, CT (500 ng/ml), CT A
subunit (1 lg/ml) and cAMP derivatives [8-Br-cAMP
(100 lM), 6-Bnz-cAMP (50 lM) and 8-CPT-20-O-Me-
cAMP (50 lM)] were added. For selective inhibition of
the protein kinase A (PKA) signaling pathway, DCs
were pretreated with H-89 (10 lM) before being treated
with MDP for 30 min. Culture supernatants were har-
vested for ELISA and immunoblotting and cell lysates
were collected for immunoblotting and real-time quan-
titative PCR (qPCR).
Cytokine measurements
Cytokines were measured using ELISA kits according to
the manufacturer’s instructions (R&D Systems).
Immunoblotting
Cells were lyzed in RIPA buffer supplemented with com-
plete protease inhibitor cocktail (Roche, Basel, Switzer-
land). Supernatants were mixed with loading buffer and
then separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred to polyvinylidene fluo-
ride membranes (Millipore, Billerica, MA). Membranes
were incubated with antibodies against all forms of IL-1b
or caspase-1 (1 : 1000 dilution). Protein bands were
detected using an ECL kit (Thermo Fisher Scientific).
Membranes were removed using restore stripping buffer
(Thermo Scientific) and re-probed with antibody against
GAPDH (1 : 5000) or b-actin (1 : 5000) as a loading
control. The intensities of blots were measured by using
the IMAGEJ program (National Institutes of Health,
Bethesda, MD). Intensities of all samples were normalized
by those of their loading control and then the final
numerical values were calculated as relative values against
the mean value of Nod2-deficient samples.
Real-time qPCR
RNA was extracted using an E.Z.N.A. Total RNA Kit I
(Omega bio-tek, Norcross, GA) and cDNA was then gen-
erated from the isolated RNA using a High-capacity
RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA).
The cDNA was used for real-time qPCR with specific pri-
mer sets and SYBR Green PCR Master Mix (Applied
Biosystems) according to the manufacturer’s instruction
for StepOnePlus Real-Time PCR systems (Applied Biosys-
tems). The real-time qPCR primers (Invitrogen, Carlsbad,
CA) were as follows: IL-1b (50-CAACCAACAAGTGA-
TATTCTCCATG-30 and 50-GATCCACACTCTCCAGCT
GCA-30) and GAPDH (50-TGCGACTTCAACAGCAACT
C-30 and 50-GCCTCTCTTGCTCAGTGTCC-30). The real-
time qPCR conditions for mRNA quantification were 95°
for 10 min, followed by 40 cycles of denaturation at 95°
for 15 seconds and annealing and extension at 60° for
1 min. The cycle threshold (Ct) values of respective sam-
ples were normalized internally using the average Ct value
of GAPDH.
Statistical analyses
Statistical analyses were performed using GRAPHPAD PRISM
software (GraphPad Software, San Diego, CA). For cyto-
kine comparisons, linear regression with a 95% confi-
dence interval, and unpaired, two-tailed Student’s t-test
were used. We examined differences in the results
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between groups of individual animals using the non-para-
metric Mann–Whitney test. No samples or animals were
excluded from the analyses. Differences with P < 005
were considered statistically significant.
Results
Symbiotic bacteria contribute to the efficacy of oral
immunization with antigen and cholera toxin
We previously showed that antibiotic treatment reduces
the efficacy of oral immunization with the model antigen,
HSA and CT as an adjuvant.16 Because treatment with
antibiotics does not completely deplete bacteria in the
gastrointestinal tract,25 we compared immune responses
between SPF and GF mice after oral immunization with
HSA and CT. Consistent with previous results following
antibiotic treatment,12,16 the amounts of HSA-specific IgG
in the plasma of GF mice were reduced when compared
with those observed in conventionally raised SPF mice
(Fig. 1a). In addition, when mice were given HSA or CT
alone, the SPF mice failed to produce HSA-specific IgG
(see Supplementary material, Fig. S1). These data confirm
that commensal bacteria play an important role in the
CT-mediated adjuvant effect on orally injected antigen.
Moreover, ex vivo re-stimulation of splenocytes derived
from SPF mice with HSA showed increased production
of the Th1 cytokine interferon-c, the Th2 cytokine IL-5
and the Th17 cytokine IL-17 in splenocytes, whereas the
induction of T-cell cytokines was significantly suppressed
in splenocytes from GF mice (Fig. 1b). These results indi-
cate that symbiotic bacteria play an important role in
promoting the adjuvant activity of CT after oral immu-
nization.
Nod2 receptor contributes to the adjuvant activity of
cholera toxin
To investigate the contribution of Nod2 to oral immu-
nization with antigen and CT, WT and Nod2–/– mice
were orogastrically immunized with HSA and CT. The
analysis showed impaired antigen-specific antibody pro-
duction in plasma from Nod2/ mice when compared
with that in WT mice (Fig. 2a, and see Supplementary
material, Fig. S2). In addition, the amounts of antigen-
specific IgA in the feces of Nod2/ mice were less than
in the feces of WT mice (Fig. 2b). In line with these anti-
body responses, the production of IL-5 and IL-17,
induced by antigen re-stimulation, was lower in spleno-
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Figure 1. Symbiotic bacteria are critical for the oral adjuvant activity of cholera toxin. (a) The levels of human serum albumin (HSA) -specific
IgG were analyzed in plasma obtained from germ-free (GF) (n = 7) and conventionally raised (specific pathogen-free; SPF) (n = 5) mice on day
14 after oral immunization with 10 mg of HSA and 10 lg of cholera toxin (CT). The left panel shows the relative amounts of antigen-specific
IgG in the serially diluted plasma as means  SEM of the optical density at 405 nm (OD405 nm). The right panel displays HSA-specific IgG in
the plasma diluted 625-fold. Each dot in the right panel represents an individual mouse and the means are displayed as a line. (b) Splenocytes
isolated from immunized GF and SPF mice on day 14 after immunization were re-stimulated with 500 lg/ml of HSA. Interleukin-5 (IL-5), IL-17
and interferon-c (IFN-c) were measured in triplicate supernatant samples on day 4 after stimulation; values represent means  SD. The results
are representative of two independent experiments. *P < 005, **P < 001 and ***P < 0001 by Mann–Whitney test (a) and two-tailed Student’s
t-test (b). ND, not detected.
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mice (Fig. 2c). The amount of interferon-c produced
after antigen re-stimulation was also reduced in Nod2-de-
ficient splenocytes when compared with that in WT
splenocytes, although the difference was not statistically
significant (Fig. 2c). These data suggest that Nod2 recog-
nition of the symbiotic bacteria is important for the adju-
vant activity induced by oral immunization with CT.
Nod2 ligand and cholera toxin act synergistically to
enhance IL-1b production in DCs
Because Nod2 in CD11c+ cells plays an important role in
the adjuvant activity of CT administered via the nasal
route,16 we examined the regulation of cytokine produc-
tion by the Nod2 ligand MDP and CT in in vitro experi-
ments using bone-marrow-derived DCs. To mimic
conditions in the intestinal tract after oral immunization,
we pretreated DCs with microbe-associated molecular
patterns for 30 min and then stimulated the cells with
CT. Sequential treatment with MDP and CT led to a syn-
ergistic induction of IL-1b secretion, but not of tumor
necrosis factor-a (Fig. 3a). Unlike IL-1b, which was not
induced by treatment of MDP alone, IL-12p40 was
induced by single treatment with both MDP and CT.
Increased secretion of IL-12p40 from cells sequentially
treated with MDP and CT can be ascribed to cumulative
stimulation by MDP and CT, rather than to synergistic
enhancement (Fig. 3a). In contrast to MDP, the ability of
multiple TLR agonists including those for TLR1/2, TLR2/
6, TLR3, TLR4 and TLR9 to stimulate the production of
IL-1b was minimally or not enhanced by CT (see Supple-
mentary material, Fig. S3a,b). To examine the kinetics
and Nod2-dependence of IL-1b production by MDP and
CT stimulation, we pretreated DCs from WT and Nod2/
 mice with MDP or medium and then treated the cells
with CT or control. Treatment with MDP and CT
induced IL-1b production in a synergistic manner com-
pared with treatment with MDP or CT alone in WT DCs
(Fig. 3b). In contrast, the enhancement of IL-1b produc-
tion by MDP and CT was not observed in DCs from
Nod2/ mice (Fig. 3b).
CT enhances IL-1b production by increasing pro-IL-
1b expression and caspase-1 activation
To understand the mechanism by which CT enhances the
secretion of IL-1b in MDP-stimulated DCs, we first
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Figure 2. Nod2 plays a crucial role in promot-
ing the adjuvant activity of cholera toxin. (a,
b) Wild-type (WT) (n = 5 or 7) and Nod2/
(n = 4) mice were orogastrically immunized
with 10 mg of human serum albumin (HSA)
and 10 lg of cholera toxin (CT), and plasma
and feces were collected on day 14 after oral
immunization. The relative amounts of anti-
gen-specific IgG (a) and IgA (b) were mea-
sured in serially diluted plasma and feces
(100 mg/ml in phosphate-buffered saline),
respectively, and the results are displayed in
the left panels. Right panels show HSA-specific
IgG (a) and IgA (b) in the plasma diluted
625-fold and 5-fold, respectively. Each dot in
the right panels represents an individual
mouse, and the means are displayed as a line.
(c) Splenocytes were isolated from WT and
Nod2/ mice on day 14 after immunization
and then re-stimulated with or without HSA
for 4 days. The amounts of interleukin-5 (IL-
5), IL-17 and interferon-c (IFN-c) in triplicate
supernatant samples were measured by ELISA.
The results are representative of two (b) or
three (a, c) independent experiments. Data are
shown as means  SEM (a, b) or SD (c).
*P < 005, **P < 001 and ***P < 0001 by
Mann–Whitney test (a, b) and by two-tailed t-
test (c). ND, not detected. NS, not significant.
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stimulated with MDP or LPS followed by treatment with
CT by immunoblotting. In the absence of CT stimulation,
there was little or no induction of pro-IL-1b by MDP
whereas LPS induced pro-IL-1b (Fig. 4a). In contrast, CT
treatment induced robust production of pro-IL-1b in
DCs pretreated with MDP compared with DCs treated
with CT alone (Fig. 4a). Importantly, the enhancement of
pro-IL-1b production in MDP-stimulated DCs by CT was
not observed in the absence of Nod2 (Fig. 4a), indicating
that the synergism between MDP and CT requires the
expression of Nod2 in DCs. In contrast to MDP, treat-
ment with CT did not enhance the production of pro-IL-
1b induced by LPS (Fig. 4a), consistent with previous
results (see Supplementary material, Fig. S2). To deter-
mine whether CT enhances the expression of Il1b mRNA,
we pretreated DCs from WT and Nod2/ mice with
MDP or medium and then treated the cells with CT or
not. Sequential treatment with MDP and CT induced Il1b
mRNA in a synergistic manner compared with treatment
with MDP or CT alone in WT DCs (Fig. 4b), which par-
allels that observed with IL-1b protein release (Fig. 3b).
As expected, the enhancement of Il1b mRNA production
by MDP and CT was not observed in DCs from Nod2/
mice (Fig. 4b).
The secretion of mature IL-1b is regulated through a
two-step process that includes the induction of pro-IL-1b
and the proteolytic activation of caspase-1, which cleaves
pro-IL-1b.26 To determine whether MDP and CT also
regulate the activation of caspase-1, we assessed the pro-
cessing of caspase-1 and production of pro-IL-1b in DCs
in the presence and absence of MDP and/or CT stimula-
tion by immunoblotting. Consistent with results shown
in Fig. 4(a), CT enhanced the production of pro-IL-1b in
DCs pre-stimulated with MDP (Fig. 4c). Importantly,
treatment with CT induced the proteolytic activation of
caspase-1 in untreated and MDP-treated DCs (Fig. 4c).
These results indicate that CT regulates the release of IL-
1b by enhancing both the production of pro-IL-1b and
inducing the activation of caspase-1 in MDP-stimulated
DCs.
CT enhances the production of IL-1b via cAMP/PKA
signaling
Cholera toxin stimulates adenylate cyclase to increase the
intracellular cAMP concentration, which has been linked
to its adjuvant activity.1,4 Elevated intracellular cAMP in
turn stimulates PKA or Rap guanine nucleotide exchange
factors [also known as exchange protein directly activated
by cAMP (Epac) 1 and 2], which regulate specific cellular
functions.9,27 To determine whether cAMP, PKA and/or
Epac are involved in MDP and CT-mediated IL-1b
induction, we treated DCs with cell-permeable cAMP
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Figure 3. Nod2 ligand and cholera toxin act synergistically to enhance IL-1b production in dendritic cells (DCs). (a, b) Bone-marrow-derived
DCs from wild-type (WT) (a, b) and Nod2/ (b) mice were first treated with muramyl dipeptide (MDP) (10 lg/ml) or left untreated, and,
30 min later, the cells were either stimulated with cholera toxin (CT0 (05 lg/ml) or left unstimulated. The supernatants were collected at 24 hr
(a) or at the indicated time-points (b) after CT addition. The indicated cytokines in triplicate supernatant samples were measured by ELISA.
Results are representative of two (b) or three (a) independent experiments. Data are shown as means  SD. *P < 005, **P < 001 and
***P < 0001 by two-tailed t-test for comparisons between all samples (a) and between sequential treatment with MDP and CT and treatment
with CT alone (b). ND, not detected.
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cAMP), or Epac activator (8-CPT-20-O-Me-cAMP) after
pretreatment with MDP. Like CT, treatment with 8-
bromo-cAMP or N6-benzoyl-cAMP enhanced the ability
of MDP to induce the secretion of IL-1b (Fig. 5a). In
contrast, treatment with 8-CPT-20-O-Me-cAMP did not
enhance the secretion of IL-1b (Fig. 5b). These results
suggest that CT enhances pro-IL-1b production via cAMP
and PKA, but not Epac activation. Consistent with these
observations, treatment with 8-bromo-cAMP or N6-ben-
zoyl-cAMP, but not 8-CPT-20-O-Me-cAMP, enhanced the
ability of MDP to induce the production of pro-IL-1b
(Fig. 5b). To confirm the role of the PKA signaling path-
way in IL-1b induction by MDP and CT, DCs were trea-
ted with a selective inhibitor of PKA, H-89, before
sequential stimulation with MDP and CT. Consistent
with results obtained with the use of an activator of PKA,
the ability of CT to synergize with MDP in the produc-
tion of IL-1b in DCs was suppressed by pretreatment
with H-89 (Fig. 5c). Collectively, these results indicate
that CT enhances the production of IL-1b in MDP-stim-
ulated DCs through cAMP/PKA signaling.
Nod2 is required for IL-1b induction after oral
immunization with antigen and cholera toxin
To determine whether the production of IL-1b is induced
in response to oral immunization in vivo, we orogastri-
cally immunized mice with HSA and CT, and then the
spleens were isolated at the indicated time-point to exam-
ine the levels of Il1b mRNA. The amounts of Il1b mRNA
in the spleens increased by 3 days following oral immu-
nization and declined to basal levels by 9 days following
oral immunization (Fig. 6a). To examine whether Nod2
is involved in the induction of IL-1b, the expression of
pro-IL-1b was examined in the spleens from WT and
Nod2/ mice on day 3 after oral immunization with
antigen and CT. As shown in Fig. 6(b), pro-IL-1b expres-
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Figure 4. Cholera toxin (CT) enhances interleukin-1b (IL-1b) production by increasing pro-IL-1b expression and caspase-1 activation. (ac).
Bone-marrow-derived dendritic cells from wild-type (WT) (a–c) and Nod2/ (a,b) mice were treated with muramyl dipeptide (MDP) (10 lg/
ml), lipopolysaccharide (LPS) (100 ng/ml) or left untreated, and, 30 min later, the cells were either stimulated with CT (05 lg/ml) or left
unstimulated. Samples were collected at 18 hr (a) or at the indicated time-points (b, c) after CT addition. (a, c) Pro-IL-1b and GAPDH were
detected in cell lysates and pro-caspase-1 and p20 (the active form of caspase-1) were analyzed in supernatants by immunoblotting. GAPDH was
used as a loading control. (b) The amount of Il1b mRNA was determined by real-time quantitative PCR and normalized relative to Gapdh
expression. Data are shown as means  SD. Results are representative of two independent experiments.
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mice compared with those of control WT mice. Likewise,
when we investigated Peyer’s patches isolated from ileum
on day 1 after oral immunization, deficiency of Nod2
reduced the pro-IL-1b expression compared with that of
control Peyer’s patches (Fig. 6c). These results suggest
that oral immunization with antigen and CT increases IL-
1b expression in the spleen and Peyer’s patches via Nod2.
IL-1b is important for the adjuvant activity of CT
To determine the role of IL-1b in the adjuvant activity of
CT, we orogastrically immunized WT and Il1b/ mice
with HSA and CT. Similar to what was observed in
Nod2/ mice, the production of antigen-specific IgG was
impaired in Il1b/ mice compared with that detected in
WT mice (Fig. 7a). Moreover, the production of T-cell
cytokines, interferon-c, IL-5 and IL-17, which was
increased by ex vivo antigen re-stimulation, was markedly
reduced in splenocytes from IL-1b-deficient mice when
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Figure 5. Cholera toxin (CT) enhances the production of inter-
leukin-1b (IL-1b) in muramyl dipeptide (MDP) -stimulated den-
dritic cells (DCs) via cAMP/protein kinase A (PKA) signaling. (ac)
Bone-marrow-derived dendritic cells were treated with MDP (10 lg/
ml) or left untreated, and, 30 min later, the cells were either stimu-
lated with CT (05 lg/ml), CT A subunit (CTA; 1 lg/ml), 8-Br-
cAMP (cAMP; 100 lM), 6-Bnz-cAMP (Bnz; 50 lM), 8-CPT-20-O-
Me-cAMP (CPT; 50 lM) or left unstimulated. (c) Bone-marrow-
derived dendritic cells were pretreated with the PKA inhibitor H-89
(10 lM) at 30 min before sequential addition of MDP and CT. Cell
lysates and supernatants were collected at 18 hr (b) or 24 hr (a, c)
after CT addition, respectively. (a, c) IL-1b in triplicate supernatant
samples was measured by ELISA. (b) Pro-IL-1b and GAPDH were
detected in cell lysates by immunoblotting. GAPDH was used as a
loading control. (a, c) Data are shown as means  SD. ND, not
detected. *P < 005, **P < 001 and *** P < 0001 by two-tailed Stu-
dent’s t-test for comparisons between sequential treatment with
MDP and CT and treatment with CT alone or between sequential





















Time after immunization (days)


































Figure 6. Interleukin-1b (IL-1b) expression induced by oral immu-
nization with antigen and cholera toxin (CT) depends on Nod2. (a–
c) Wild-type (WT) (n = 5, n = 3, or n = 2) (b, c) and Nod2/
(n = 3 or n = 2) mice were orogastrically immunized with human
serum albumin (HSA) and CT, and spleens were collected at the
indicated time-points (a) and on day 3 (b) after oral immunization.
(c) Peyer’s patches were isolated from ileum on day 1 after oral
immunization. (a) Il1b mRNA expression was analyzed by real-time
quantitative PCR. Gapdh expression was used to normalize data. (b,
c) Pro-IL-1b protein was detected by immunoblotting, with b-actin
as an internal control. Each lane represents an individual mouse.
The relative intensities of pro-IL-1b blots indicated below each lane
were normalized by their b-actin amounts and then were displayed
as relative values against the mean value of Nod2-deficient samples.
The results are representative of two independent experiments.
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These results indicate that IL-1b plays an important role
in the adjuvant activity of CT administered orally.
Discussion
The efficacy of mucosal vaccines differs in various geo-
graphical regions.28,29 There have been several hypotheses
to explain the variation in immune responses after muco-
sal vaccination. For example, malnutrition may contribute
to oral vaccination in developing countries.30 In addition,
an unsanitary environment in developing countries could
lead to persistent exposure of people to various enteric
pathogens, which may be associated with reduced efficacy
of mucosal vaccines.31 A major finding of this study is
that the microbiota plays a crucial role in oral immuniza-
tion with antigen and CT. Hence, our results raise the
possibility that differences in the composition of the
microbiota among individuals may affect the efficacy of
oral vaccination. The composition of the gut microbiota
varies widely among individuals and can be affected by
various environmental factors, including dietary habits,
pathogen infections and geographical location.32 Well-de-
signed epidemiological studies are needed to examine the
effects of the microbiota on vaccination efficacy and
whether the microbiota plays a role; it will be important
to design appropriate vaccine protocols to overcome any
limitations to elicit protective immune responses due to
specific microbiota profiles.
Successful vaccination is the result of orchestrated
innate and adaptive immune responses.33 Given that
innate immune signals modulate the magnitude, quality
and duration of adaptive responses,33 many microbe-asso-
ciated molecular patterns, which promote innate immune
signals through host pattern recognition receptors,34 have
been studied as adjuvant candidates and, among them, a
TLR ligand adjuvant has been approved for clinical use
with a human papillomavirus vaccine.33,35 MDP, a Nod2
ligand, was originally identified as the active component
in the adjuvanticity of complete Freund’s adjuvant and
several studies have reported its potential for use as a
non-mucosal adjuvant.22,36 We recently showed that,
upon immunization via the nasal route, MDP enhanced
the adjuvant activity of CT, even though MDP itself has
no mucosal adjuvant activity.16 Likewise, the significance
of the Nod2 receptor in the adjuvant activity of CT via
the oral route was confirmed in this study, which suggests
that MDP delivered in concert with CT may exhibit
potent mucosal adjuvant activity. Hence, the development
of less pyrogenic and more potent adjuvants based on
derivatives of CT and MDP should be considered. For
example, like CTA1-DD, a fusion protein of CT A sub-
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Figure 7. Interleukin-1 b (IL-1b) plays a crucial role in promoting the adjuvant activity of cholera toxin (CT). (a) The relative amounts of
human serum albumin (HSA) -specific IgG were measured in the plasma of wild-type (WT) (n = 6) and Il1b/ (n = 5) mice on day 14 after
oral immunization with HSA and CT. The left panel shows the relative amounts of antigen-specific IgG in the serially diluted plasma as
means  SEM. The right panel displays antigen-specific IgG in the plasma diluted 625-fold. Each dot in the right panel represents an individual
mouse, and the means are displayed as a line. (b) Splenocytes were isolated from WT and Il1b/ mice on day 14 after immunization and then
re-stimulated with HSA or left unstimulated for 4 days. Interleukin-5 (IL-5), IL-17 and interferon-c (IFN-c) in triplicate supernatant samples
were measured by ELISA. Data are shown as means  SD. The results are representative of three independent experiments. *P < 005,
**P < 001 and ***P < 0001 by Mann–Whitney test (a) and by two-tailed Student’s t-test (b). ND, not detected.
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aureus,37 a molecule that combines the CT A subunit and
MDP derivatives might be effective in providing enhanced
adjuvant activity.
Dendritic cells and macrophages are important media-
tors of the adjuvant activity of CT.38,39 Consistently,
expression of Nod2 receptor in CD11c+ cells, including
DCs, is required for optimal elicitation of an adaptive
immune response by nasal immunization with antigen
and CT.16 In the current work, we show that Nod2 is also
important for the induction of antibody responses in
response to oral immunization with antigen and CT. Fur-
thermore, we found that IL-1b is a critical mediator of
the adjuvant activity of CT induced via the oral route.
Mechanistically, the production of IL-1b was induced
synergistically by stimulation of DCs with the Nod2 ago-
nist and CT via induction of pro-IL-1b and caspase-1
activation. These observations suggest that CT induces its
adjuvant activity, at least in part, by enhancing the Nod2-
stimulatory activity of the microbiota to induce IL-1b in
intestinal DCs. IL-1b is a pleiotropic cytokine that has a
pivotal role in the onset and development of immune
responses.40 In line with our observations, administration
of recombinant IL-1b induces adjuvant activity in both
mucosal and systemic immunization protocols.41–43 Even
recombinant Lactobacillus casei, which was engineered to
produce biologically active IL-1b, can function as an
adjuvant in oral immunization.44 However, the use of IL-
1b as an adjuvant has never been pursued because of its
overwhelming inflammatory effects.42 CT induced IL-1b
production at least in part by enhancing the expression of
pro-IL-1b in MDP-stimulated DCs via a cAMP–PKA-de-
pendent pathway. Many other adjuvants originating from
bacterial toxins, such as heat-labile toxin from Escherichia
coli, and pertussis toxin and adenylate cyclase toxin from
Bordetella pertussis, either directly or indirectly increase
the concentration of intracellular cAMP.5,45–47 Although
correlation between the increased cAMP and their adju-
vanticity is controversial,46,47 our observations with CT
suggest that Nod2 ligand or bacteria having high Nod2
activity could also improve the adjuvant activity of others
toxins through induction of IL-1b production.
Author Contributions
DK and GN conceived this study. DK performed most of
the experiments. YMK and SUS helped with the experi-
ments. WUK and JHP helped in the design of several
experiments and provided critical advice. DK, SUS and
GN wrote the manuscript, with contributions from all of
the authors.
Funding
This work was supported by National Institutes of Health
grants (Grants R01AI063331 and R01DK091191 to GN),
National Research Foundation of Korea grants funded by
the Ministry of Science, ICT and Future Planning (Grants
2015R1A3A2032927 to WUK and 2016R1C1B2008089 to
SUS), a National Research Foundation of Korea grant
funded by the Ministry of Education (Grant
2017R1D1A1B04033009 to DK), and Creative-Pioneering
Researchers Program through Seoul National University
(DK).
Acknowledgements
We thank Lisa Haynes and Jong-Hyoek Jung for animal
husbandry and the University of Michigan GF Animal
Core Facility and Host Microbiome Initiative for support.
Disclosures
The authors have no conflicting interests to declare.
References
1 Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera.
Nature 1981; 292:413–7.
2 Holmgren J, Lonnroth I, Svennerholm L. Tissue receptor for cholera exotoxin: postu-
lated structure from studies with GM1 ganglioside and related glycolipids. Infect
Immun 1973; 8:208–14.
3 Katada T, Ui M. Direct modification of the membrane adenylate cyclase system by
islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad
Sci USA 1982; 79:3129–33.
4 Cassel D, Pfeuffer T. Mechanism of cholera toxin action: covalent modification of the
guanyl nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci
USA 1978; 75:2669–73.
5 Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia
coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J
Immunol 1992; 22:2277–81.
6 Xu-Amano J, Kiyono H, Jackson RJ, Staats HF, Fujihashi K, Burrows PD et al. Helper
T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid
and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.
J Exp Med 1993; 178:1309–20.
7 Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Yamamoto M, Fujihashi K et al. A
nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal
immunity. Proc Natl Acad Sci USA 1997; 94:5267–72.
8 Datta SK, Sabet M, Nguyen KPL, Valdez PA, Gonzalez-Navajas JM, Islam S et al.
Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against
inhalation anthrax. Proc Natl Acad Sci USA 2010; 107:10638–43.
9 Li X, Murray F, Koide N, Goldstone J, Dann SM, Chen J et al. Divergent requirement
for Gas and cAMP in the differentiation and inflammatory profile of distinct mouse
Th subsets. J Clin Invest 2012; 122:963–73.
10 Martin M, Metzger DJ, Michalek SM, Connell TD, Russell MW. Distinct cytokine regu-
lation by cholera toxin and type II heat-labile toxins involves differential regulation of
CD40 ligand on CD4+ T cells. Infect Immun 2001; 69:4486–92.
11 Kawamura YI, Kawashima R, Shirai Y, Kato R, Hamabata T, Yamamoto M et al. Cho-
lera toxin activates dendritic cells through dependence on GM1-ganglioside which is
mediated by NF-jB translocation. Eur J Immunol 2003; 33:3205–12.
12 Bromander A, Holmgren J, Lycke N. Cholera toxin stimulates IL-1 production and
enhances antigen presentation by macrophages in vitro. J Immunol 1991; 146:2908–14.
13 Kamada N, Seo S-U, Chen GY, Nunez G. Role of the gut microbiota in immunity and
inflammatory disease. Nat Rev Immunol 2013; 13:321–35.
14 Kim D, Zeng MY, Nu~nez G. The interplay between host immune cells and gut micro-
biota in chronic inflammatory diseases. Exp Mol Med 2017; 49:e339.
15 Oh Jason Z, Ravindran R, Chassaing B, Carvalho Frederic A, Maddur Mohan S, Bower
M et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses
to seasonal influenza vaccination. Immunity 2014; 41:478–92.
16 Kim D, Kim Y-G, Seo S-U, Kim D-J, Kamada N, Prescott D et al. Nod2-mediated
recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin.
Nat Med 2016; 22:524–30.
ª 2019 John Wiley & Sons Ltd, Immunology, 158, 219–229228
D. Kim et al.
17 Shaw MH, Reimer T, Kim Y-G, Nu~nez G. NOD-like receptors (NLRs): bona fide intra-
cellular microbial sensors. Curr Opin Immunol 2008; 20:377–82.
18 Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J et al. Host recognition
of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn0s dis-
ease. J Biol Chem 2003; 278:5509–12.
19 Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G et al. Nod2 is a
general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol
Chem 2003; 278:8869–72.
20 Park J-H, Kim Y-G, McDonald C, Kanneganti T-D, Hasegawa M, Body-Malapel M
et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2
but not TLRs. J Immunol. 2007; 178:2380–6.
21 Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nu~nez G et al. A critical
role of RICK/RIP2 polyubiquitination in Nod-induced NF-jB activation. EMBO J
2008; 27:373–83.
22 Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, Selvanantham T et al.
Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 2008;
181:7925–35.
23 Pavot V, Rochereau N, Resseguier J, Gutjahr A, Genin C, Tiraby G et al. Cutting edge:
new chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity. J
Immunol 2014; 193:5781–5.
24 Kim D, Kim SH, Park E-J, Kim J, Cho S-H, Kagawa J et al. Suppression of allergic
diarrhea in murine ovalbumin-induced allergic diarrhea model by PG102, a water-sol-
uble extract prepared from Actinidia arguta. Int Arch Allergy Immunol 2009; 150:164–
71.
25 Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M et al. Vancomycin-resis-
tant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment
in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120:4332–41.
26 He Y, Hara H, Nu~nez G. Mechanism and regulation of NLRP3 inflammasome activa-
tion. Trends Biochem Sci 2016; 41:1012–21.
27 de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A et al.
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP.
Nature 1998; 396:474–7.
28 Steele AD, Patel M, Parashar UD, Victor JC, Aguado T, Neuzil KM. Rotavirus vaccines
for infants in developing countries in Africa and Asia: considerations from a World
Health Organization-Sponsored Consultation. J Infect Dis 2009; 200:S63–9.
29 Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: les-
sons from a live cholera vaccine. BMC Biol 2010; 8:129.
30 Prendergast AJ. Malnutrition and vaccination in developing countries. Philos Trans R
Soc Lond B Biol Sci 2015; 370:20140141.
31 Korpe PS, Petri WA. Environmental enteropathy: critical implications of a poorly
understood condition. Trends Mol Med 2012; 18:328–36.
32 Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA et al. Origins
and evolution of the Western diet: health implications for the 21st century. Am J Clin
Nutr 2005; 81:341–54.
33 Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23:1804–13.
34 Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immu-
nity. Immunol Rev 2009; 227:221–33.
35 Schwarz T. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervi-
cal cancer vaccine, Cervarix. Adv Ther 2009; 26:983–98.
36 Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant
activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974;
59:1317–25.
37 Mowat AMI, Donachie AM, J€agewall S, Sch€on K, L€owenadler B, Dalsgaard K et al.
CTA1-DD-immune stimulating complexes: a novel, rationally designed combined
mucosal vaccine adjuvant effective with nanogram doses of antigen. J Immunol 2001;
167:3398–405.
38 Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A, De Magistris
MT. Cholera toxin induces maturation of human dendritic cells and licences them for
Th2 priming. Eur J Immunol 2000; 30:2394–403.
39 Yamamoto M, Kiyono H, Yamamoto S, Batanero E, Kweon MN, Otake S et al. Direct
effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a
nontoxic cholera toxin mutant. J Immunol 1999; 162:7015–21.
40 Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095–147.
41 Staats HF, Ennis FA. IL-1 is an effective adjuvant for mucosal and systemic immune
responses when coadministered with protein immunogens. J Immunol 1999; 162:6141–
7.
42 Kusnecov AW, Rossi-George A. Potentiation of interleukin-1b adjuvant effects on the
humoral immune response to antigen in adrenalectomized mice. NeuroImmunoModula-
tion 2001; 9:109–18.
43 Rothel JS, Seow HF, Lightowlers MW, Parry BW, Gauci C, Hurst L et al. The use of
recombinant ovine IL-1b and TNF-a as natural adjuvants and their physiological effects
in vivo. Immunol Cell Biol 1998; 76:167–72.
44 Kajikawa A, Masuda K, Katoh M, Igimi S. Adjuvant effects for oral immunization pro-
vided by recombinant Lactobacillus casei secreting biologically active murine inter-
leukin-1b. Clin Vaccine Immunol 2010; 17:43–8.
45 Johnson AM, Kaushik RS, Francis DH, Fleckenstein JM, Hardwidge PR. Heat-labile
enterotoxin promotes Escherichia coli adherence to intestinal epithelial cells. J Bacteriol
2009; 191:178–86.
46 Liang S, Hajishengallis G. Heat-labile enterotoxins as adjuvants or anti-inflammatory
agents. Immunol Invest 2002; 39:449–67.
47 Bagley KC, Abdelwahab SF, Tuskan RG, Fouts TR, Lewis GK. Pertussis toxin and the
adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived den-
dritic cells and dominantly inhibit cytokine production through a cAMP-dependent
pathway. J Leukoc Biol 2002; 72:962–9.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure. S1. Production of antigen-specific IgG is
induced by oral immunization with both human serum
albumin (HSA) and cholera toxin (CT), but not CT or
HSA alone or mock control.
Figure. S2. Productions of antigen-specific IgG1, IgG2b
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